

REVIEW

Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders

P. Valent

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria

Clinical & Experimental Allergy

Summary

Several different risk factors and conditions may predispose to severe life-threatening anaphylaxis. Systemic mastocytosis (SM) is one such condition. Although many SM patients are suffering from mild or even no mediator-related symptoms, others have recurrent episodes of severe anaphylaxis, with clear signs of a mast cell activation syndrome (MCAS) despite prophylactic therapy with anti-mediator-type drugs. In several of these patients, an IgE-dependent allergy is diagnosed. The severity and frequency of MCAS reactions neither correlate with the burden of neoplastic mast cells nor with the levels of specific IgE or the basal tryptase level. However, there is a relationship between severe anaphylaxis in SM and the type of allergen. Notably, many of these patients suffer from hymenoptera venom allergy. Currently recommended therapies include the prophylactic use of anti-mediator-type drugs, long-term immunotherapy for hymenoptera venom allergic patients, and epinephrine-self-injector treatment for emergency situations. In patients who present with an excess burden of mast cells, such as smouldering SM, cytoreductive therapy with cladribine (2CdA) may reduce the frequency of severe events. For the future, additional treatment options, such as IgE-depletion or the use of tyrosine kinase inhibitors blocking IgE-dependent mediator secretion as well as KIT activation, may be useful alternatives.

Correspondence:

Peter Valent, Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria.
E-mail: peter.valent@meduniwien.ac.at
Cite this as: P. Valent, *Clinical & Experimental Allergy*, 2014 (44) 914–920.

Introduction

Mastocytosis is a term that defines a rare group of disorders characterized by abnormal expansion and accumulation of tissue mast cells (MC) in one or more organ systems [1–6]. In many patients, typical skin involvement, usually in form of maculopapular lesions, is found. Cutaneous mastocytosis (CM) usually develops in childhood and has a very favourable prognosis. In many of these patients, cutaneous lesions resolve spontaneously during or after puberty. Systemic mastocytosis (SM) is usually diagnosed in adulthood and is characterized by internal organ involvement, with multifocal compact infiltrates of MC [1–6]. In most cases, the bone marrow (BM) is affected [1–6]. Skin lesions are detectable in a majority of adult patients with SM. In most patients, the *KIT* mutation D816V is detected in clonal cells [7–11]. Neoplastic MC in these patients usually display cytomorphologic signs of atypia and express the LFA-2 antigen (CD2) and/or the IL-2

receptor alpha chain (CD25) [1–6, 12–15]. In almost all patients fulfilling WHO criteria for SM, the basal serum tryptase level is persistently elevated (>20 ng/mL) [16–18]. The following subtypes of SM are listed in the current classification of the World Health Organization (WHO): indolent systemic mastocytosis (ISM), SM with an associated clonal haematologic non-MC-lineage disease (SM-AHNMD), aggressive SM (ASM) and MC leukaemia (MCL) [19–23]. The smouldering variant of SM (SSM) was initially presented as a provisional subtype of ISM [19, 20]. Later, however, SSM has been recognized as a separate category of SM [21, 24]. Table 1 shows the current classification of mastocytosis as defined by the consensus group [3, 19–23].

In all variants of SM, the release of several different proinflammatory and vasoactive mediators from MC may cause clinical problems [25–30]. Depending on comorbidities such as an allergic disease and other factors, the symptoms vary in severity, and range from mild flushing or headache to severe hypotension or even life-threatening

Table 1. Classification of mastocytosis*

Cutaneous mastocytosis (CM)
Maculopapular CM (MPCM) = urticaria pigmentosa (UP)
Diffuse CM (DCM)
Mastocytoma of skin
Systemic mastocytosis (SM)
Indolent SM (ISM)
Smouldering SM (SSM)*
SM with associated clonal haematologic non-mast cell-lineage disease (SM-AHNMD)
Aggressive SM (ASM)
Mast cell leukaemia (MCL)
Extracutaneous mastocytoma
Mast cell sarcoma

*The classification relates to the WHO classification of 2008.

However, in contrast to the WHO classification, SSM is now recognized as a separate category of SM.

anaphylaxis [25–30]. In severe cases, a MC activation syndrome (MCAS) is diagnosed [31–33]. The triggering factors often remain unknown. In other patients, a co-existing allergy is detectable [25–30] (Table 2). In many cases, therapy with anti-mediator-type drugs and MC-stabilizing drugs is sufficient to control symptoms [25–33]. In those with a documented allergy, immunotherapy (IT) may be considered and may be helpful in avoiding fatal hypotension episodes [25–30]. For all patients, strict avoidance of triggering factors is essential [25–30]. However, in some of the patients, severe or even life-threatening events occur despite adequate anti-mediator-type drugs, IT and prevention. For these patients, the optimal management remains a challenge.

The frequency and risk of severe anaphylaxis in mastocytosis

About 10–20% of all patients with SM may experience at least one episode of severe life-threatening anaphylaxis during their lifetime [28]. In some of the patients

Table 2. Factors that can provoke anaphylaxis in patients with mastocytosis

Factor*	Potential mechanism
Insect (hymenoptera) venom	IgE-dependent allergy
Microbes (bacteria, viruses and others)	Allergic reaction or direct effects on mast cells
Food	Food allergies
Pollen and other plant allergens	IgE-dependent allergy
Stress	Nerve–mast cell interactions
Cold temperature	Temperature effect on mast cells
Aspirin	Idiosyncrasy, Syk activation
Other drugs	Allergy direct effects on mast cells
Alcohol	Direct effect on mast cells
Toxins	Direct effects on mast cells

*Most of these factors can also provoke anaphylactic reactions in (allergic) patients in the absence of mastocytosis.

with SM who suffer from severe episodes of anaphylaxis and thus from MCAS, a co-existing allergy, usually an IgE-dependent disease, is diagnosed [25–30]. The frequency and severity of such reactions differ from patient to patient, and little is known about the mechanisms and triggering factors underlying hyper-responsiveness of MC in allergic patients and in patients with SM. Only a few studies have investigated a potential relationship between severe symptoms and certain genetic patterns [34–36]. Other studies have shown a relationship between certain clinical and laboratory features and the risk of anaphylaxis [37–39]. In one study, elevated tryptase levels have been associated with an increased risk of severe mediator-related events [37]. By contrast, other studies have suggested that severe anaphylaxis occurs preferentially in patients with a low burden of neoplastic MC [38]. The only well-established risk factor for recurrent severe anaphylaxis may be an overt allergy against hymenoptera venom. In fact, several different studies have shown that venom allergic patients with SM have a high risk for severe life-threatening anaphylaxis after bee or wasp stings [40–45].

Grading of anaphylaxis in mast cell disorders

Several different grading systems for anaphylaxis have been developed, such as the ‘Ring–Messmer Scale’ [46] or the ‘Müller Scale’ that can be used to grade symptoms in patients with insect venom allergy [47]. These scores may work in patients with mastocytosis suffering from anaphylaxis. In 2007, the consensus group has presented another scoring system, with the intention to optimize and standardize grading of symptoms in patients with MC disorders [21]. This grading system is useful for grading of mediator-related symptoms in all patients with SM and includes the following: grade 0 (no symptoms), grade 1 (mild, no therapy required), grade 2 (moderate, kept under control with anti-mediator therapy), grade 3 (not sufficiently controlled with therapy) and grade 4 (severe symptoms requiring hospitalization) [21]. The frequency of grade 4 events is also measured and included in the grading system: A (<1/year), B (>1/year and <1/month) and C (>1/month) [21]. Severe hypotension and MCAS may occur in any category of SM and even also in patients with CM without histologic evidence of systemic organ involvement. As mentioned, an allergen can be identified as specific trigger of anaphylaxis in a subset of cases [25–30]. The classification of ‘anaphylaxis’ in mastocytosis is thus based on the presence (+) or absence (–) of IgE-dependent allergic reactions [21].

Mast cell activation syndrome (MCAS)

MCAS can be diagnosed when (i) recurrent systemic (usually severe) symptoms of MC activation (MCA) are found,

(ii) involvement of MC can be documented, preferably by demonstrating an increase in the serum tryptase level during (or shortly after) an event, and c) the symptoms respond to therapy with anti-mediator-type or MC-stabilizing medication [31, 32, 48–52]. All three criteria must be met to diagnose MCAS [31, 32, 48, 49]. The diagnostic (minimal) increase in serum tryptase is defined by the following consensus formula: at least 20% of baseline level plus absolute 2 ng/mL [32]. For example, an increase from 10 (basal) to 16 ng/mL (measured during the event) is diagnostic because $10 + 2 (20\%) + 2 = 14$. It is important to collect a serum sample at the time of the event and to compare this value to a serum sample taken either before the event occurred or at least 2 days after complete resolution of all symptoms. In patients in whom the basal tryptase level is elevated, a search for an underlying MC disease has to be initiated [21, 32, 49].

In many cases, only 2 or even 1 of the criteria of MCAS can be documented because mediators were not measured (e.g. assay not available) or the patient did not respond to anti-mediator-type drugs. In other patients, no increase in the serum tryptase level can be demonstrated. In some of these patients, other MC-derived mediators such as plasma histamine, urinary histamine metabolites or prostaglandin D2 levels can be measured and may show an increase during anaphylactic episodes [53–56]. MC activation may also manifest as a less severe reaction so that MCAS criteria are not met, but the patients are still suffering from symptoms requiring therapy. In other words, not all anaphylactic (mediator-related, clinically relevant) symptoms can be classified as MCAS. Finally, basophil activation can also lead to severe symptoms mimicking MC activation (or even MCAS). As soon as MC activation is found, patients need to be examined for the presence of a clonal MC disorder [32]. In those in whom mastocytosis is diagnosed, the presence of clinically relevant MC activation (requiring therapy) should be indicated by the diagnostic label 'SY' (for SYmptoms) added as a subscript to the diagnosis (example: SM_{SY}) [21]. Again, however, not all patients with SM_{SY} are suffering from an overt MCAS [21, 32].

Underlying disorders and classification of MCAS

Initially, the term MCAS was reserved for patients with severe MC mediator-related symptoms in whom criteria for an underlying MC disease or other condition were not fulfilled [31]. Later, this form of MCAS was defined as idiopathic MCAS [32]. In fact, MCAS usually develops on the basis of an underlying (systemic) disease, which can be an IgE-dependent disorder, another reactive condition, or a MC neoplasm [21, 31–35, 48–52] (Table 3). The MC neoplasm is usually classified as SM. However, MCAS may also occur in patients with CM. In patients with SM, neoplastic MC usually express the activating

Table 3. Mast cell activation syndromes (MCAS): variants and features

Type of MCAS	Clinical and laboratory features
Primary MCAS	<i>KIT</i> D816V-mutated monoclonal mast cells found - Established SM: criteria to diagnose SM are fulfilled* - Established CM: criteria for CM are fulfilled but the criteria to diagnose SM are not fulfilled - Neither CM nor SM can be diagnosed, but monoclonal mast cells are found (1 or 2 minor SM criteria found)
Secondary MCAS	An underlying allergic or atopic disease is found but no monoclonal mast cells are detectable (wt <i>KIT</i>)
Idiopathic MCAS	No underlying allergy or atopy and no monoclonal (<i>KIT</i> -mutated) mast cells are detectable

SM, systemic mastocytosis; CM, cutaneous mastocytosis.

*The diagnosis SM can be made when at least one major and one minor SM criterion or at least 3 minor SM criteria are fulfilled.

KIT mutation D816V, which is considered to play a role in the autonomous expansion and survival of neoplastic MC [6–10, 57]. Moreover, *KIT* D816V has been implicated in the increased releasability of MC in SM, because *KIT* ligand-induced activation of normal MC leads to enhanced IgE-dependent mediator release [58–60]. However, in several patients with SM, no mediator-related symptoms can be recorded even if the burden of neoplastic MC is very high, which argues against a major role of *KIT* D816V in the hyper-responsiveness of MC.

Based on the underlying disease, MCAS can be classified and thus diagnosed as primary MCAS, secondary MCAS and idiopathic MCAS [31, 32, 49] (Table 3). In primary MCAS, *KIT*-mutated, clonal MC are found. The underlying disease in these cases may be CM or SM [31, 32, 49]. However, even in the absence of CM or SM, a primary MCAS can be diagnosed. In these patients, monoclonal MC are found but only one or two minor SM criteria are demonstrable, so that the diagnosis SM cannot be established [31, 32, 49] (Table 3). In such cases, the follow-up may reveal progression to an overt MC disease (usually SM). Most patients with secondary MCAS are suffering from an IgE-dependent allergy [31, 32, 49–52]. If neither an allergy or other reactive disease process nor a monoclonal MC population (*KIT*-mutated) is found, the diagnosis 'idiopathic MCAS' is appropriate (Table 3).

Treatment options and response evaluation

The most important therapeutic manoeuvre is to avoid any agents and situations that may provoke an allergic reaction [21, 32]. Patients at risk are also advised to take

prophylactic medication life-long and to carry 2 or more epinephrine-self-injectors for use in emergency situations according to prescribed instructions. Mild symptoms (grade 1) do not require any drug therapy and grade 2 symptoms can usually be kept under control with proper anti-mediator-type drugs. These mediator-targeting drugs are prescribed according to published algorithms [21, 32] and the individual situation in each case. A summary of most commonly prescribed prophylactic anti-mediator-type drugs is shown in Table 4. In patients with IgE-dependent anaphylaxis, specific immunotherapy (IT) should be considered, with recognition of potential side-effects [61–63]. Cyto-reductive agents are usually not prescribed for treatment of mediator-related events in SM. However, in MCAS patients with a huge burden of MC, like seen in SSM and ASM, cyto-reductive therapy should be considered. In fact, it has been described, that in SSM patients with MCAS, the frequency of recurrent life-threatening anaphylaxis events decrease substantially after treatment with cladribine (2CdA) [64, 65]. Aspirin has previously been considered for treatment of severe anaphylaxis in SM. However, the doses of aspirin required to suppress PGD₂ production in MC are quite high. In addition, aspirin may provoke adverse events such as gastrointestinal problems (like bleeding) and can even induce hypotension (Table 2). Therefore, aspirin should only be administered in select cases and with great caution in SM. Other drugs, including MC-stabilizing agents or glucocorticosteroids, have also been suggested. A new emerging class of MC-targeting drugs are broadly acting tyrosine kinase inhibitors (TKI), such as imatinib, PKC412 (midostaurin), dasatinib or masitinib

Table 4. Prophylactic treatment of mediator-related symptoms in patients with mastocytosis

Recommended treatment	Specific indication
Histamine receptor type 1 blocker	All patients
Histamine receptor type 2 blocker	All patients
Glucocorticosteroids	High-risk patients* Anaphylactic reactions known to be unresponsive to histamine receptor blockers
Immunotherapy (IT)	Hymenoptera venom allergy†
Cladribine (2CdA)	SM with high mast cell burden (SSM) and severe, recurrent life-threatening anaphylaxis

SM, systemic mastocytosis; SSM, smouldering SM; SM_{SY}, SM with severe mediator-related symptoms requiring therapy.

*Even in high-risk patients, glucocorticosteroids should not be prescribed routinely and only with great caution and with recognition that long-term treatment is associated with the risk of severe osteoporosis in SM.

†In patients with SM in whom a bee or wasp venom allergy is diagnosed, life-long IT is usually recommended.

[66–74]. Some of these TKI, such as PKC412, block KIT D816V activation and thus MC proliferation in patients with SM [69–71]. However, KIT D816V is resistant against most of the other TKI, including imatinib and masitinib. An interesting aspect is that PKC412 not only inhibits KIT-dependent MC proliferation but also IgE-dependent (allergen-induced) activation and mediator secretion in MC [75]. Therefore, TKI like PKC412 are considered as emerging and promising agents for patients with advanced SM, SM_{SY} and MCAS. Another approach is to deplete specific IgE in patients with SM_{SY} or MCAS [76, 77]. However, for all these agents, controlled clinical trials demonstrating efficacy and safety in SM_{SY} or MCAS are currently lacking.

Responses to anti-mediator-type therapy are classified as complete response, CR (complete resolution of symptoms), major response, MR (>50% reduction in severity or/and significant decrease in frequency of events: B→A or C→B), partial response, PR (10–50% reduction in severity; no major decrease in frequency) and no response, NR (<10% reduction; no decrease in frequency) [32].

Concluding remarks and future perspectives

Patients with clonal MC disorders, such as SM, are at relatively high risk for the development of severe life-threatening anaphylaxis (MCAS). During the past few years, substantial knowledge concerning the triggers and mechanisms underlying MC activation and thus MCAS in these patients has been accumulated. In addition, solid criteria for the diagnosis and classification of MCAS have been established. Finally, new targeted drugs suppressing MC activation and/or MC proliferation in SM have been developed and are currently tested in clinical trials. Other novel drugs are effective in depleting free (uncomplexed) specific IgE, in inhibiting mediator production or in suppressing mediator effects. For the future, the application of such drugs in defined algorithms may lead to advanced personalized medicine in MC proliferative disorders and MCAS.

Acknowledgement

This work was supported by the 'Austrian Science Fund' (FWF), Grants SFB #4611 and #SFB-F4704.

Conflict of interest

The author declares no conflict of interest.

Disclosure statement

P.V. is a consultant for a global Novartis trial examining the effects of PKC412 in advanced SM and received honoraria and research grants from Novartis and BMS.

References

- 1 Metcalfe DD. Classification and diagnosis of mastocytosis: current status. *J Invest Dermatol* 1991; 96:2S–4S.
- 2 Valent P. Biology, classification and treatment of human mastocytosis. *Wien Klin Wochenschr* 1996; 108:385–97.
- 3 Valent P, Akin C, Sperr WR *et al.* Diagnosis and treatment of systemic mastocytosis: state of the art. *Br J Haematol* 2003; 122:695–717.
- 4 Akin C, Metcalfe DD. Systemic mastocytosis. *Annu Rev Med* 2004; 55:419–32.
- 5 Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. *Leuk Res* 2001; 25:543–51.
- 6 Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. *Expert Rev Hematol* 2010; 3:497–516.
- 7 Nagata H, Worobec AS, Oh CK *et al.* Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. *Proc Natl Acad Sci USA* 1995; 92:10560–4.
- 8 Longley BJ, Tyrrell L, Lu SZ *et al.* Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. *Nat Genet* 1996; 12:312–4.
- 9 Féger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. *Int Arch Allergy Immunol* 2002; 127:110–4.
- 10 Fritsche-Polanz R, Jordan JH, Feix A *et al.* Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. *Br J Haematol* 2001; 113:357–64.
- 11 Bodemer C, Hermine O, Palmérini F *et al.* Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. *J Invest Dermatol* 2010; 130:804–15.
- 12 Escribano L, Orfao A, Diaz-Agustin B *et al.* Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. *Blood* 1998; 91:2731–6.
- 13 Valent P, Scherthaner GH, Sperr WR *et al.* Variable expression of activation-linked surface antigens on human mast cells in health and disease. *Immunol Rev* 2001; 179:74–81.
- 14 Jordan JH, Walchshofer S, Jurecka W *et al.* Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). *Hum Pathol* 2001; 32:545–52.
- 15 Sotlar K, Horny HP, Simonitsch I *et al.* CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. *Am J Surg Pathol* 2004; 28:1319–25.
- 16 Schwartz LB, Sakai K, Bradford TR *et al.* The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. *J Clin Invest* 1995; 96:2702–10.
- 17 Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. *N Engl J Med* 1987; 316:1622–6.
- 18 Sperr WR, Jordan JH, Fiegl M *et al.* Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. *Int Arch Allergy Immunol* 2002; 128:136–41.
- 19 Valent P, Horny HP, Escribano L *et al.* Diagnostic criteria and classification of mastocytosis: a consensus proposal. *Leuk Res* 2001; 25:603–25.
- 20 Valent P, Horny HP, Li CY *et al.* Mastocytosis. In Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. *World Health Organization (WHO) Classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues*. Lyon, France: IARC Press, 2001:291–302.
- 21 Valent P, Akin C, Escribano L *et al.* Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. *Eur J Clin Invest* 2007; 37:435–53.
- 22 Horny HP, Metcalfe DD, Bennett JM *et al.* Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Varderman JW, eds. *WHO classification of tumours of haematopoietic and lymphoid tissues*. France: IARC Press, Lyon, 2008:54–63.
- 23 Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. *J Allergy Clin Immunol* 2004; 114:3–11.
- 24 Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression. *Int Arch Allergy Immunol* 2002; 127:137–9.
- 25 Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. *Ann Hematol* 2002; 81:677–90.
- 26 Metcalfe DD, Schwartz LB. Assessing anaphylactic risk? Consider mast cell clonality. *J Allergy Clin Immunol* 2009; 123:687–8.
- 27 Akin C. Anaphylaxis and mast cell disease: what is the risk? *Curr Allergy Asthma Rep* 2010; 10:34–8.
- 28 Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. *Int Arch Allergy Immunol* 2012; 157:399–405.
- 29 Alvarez-Twose I, Bonadonna P, Matito A *et al.* Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. *J Allergy Clin Immunol* 2013; 131:614–5.
- 30 Gülen T, Hägglund H, Dahlén B, Nilsson G. High prevalence of anaphylaxis in patients with systemic mastocytosis – a single-centre experience. *Clin Exp Allergy* 2014; 44:121–9.
- 31 Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. *J Allergy Clin Immunol* 2010; 126:1099–104.
- 32 Valent P, Akin C, Arock M *et al.* Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. *Int Arch Allergy Immunol* 2012; 157:215–25.
- 33 Alvarez-Twose I, González-de-Olano D, Sánchez-Muñoz L *et al.* Validation of the REMA score for predicting mast

- cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. *Int Arch Allergy Immunol* 2012; **157**:275–80.
- 34 Niedozytko M, Bruinenberg M, van Doormaal JJ *et al.* Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis. *Allergy* 2011; **66**:648–57.
 - 35 Daley T, Metcalfe DD, Akin C. Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin. *Blood* 2001; **98**:880–2.
 - 36 Rausz E, Szilágyi A, Niedozytko B *et al.* Comparative analysis of IL6 and IL6 receptor gene polymorphisms in mastocytosis. *Br J Haematol* 2013; **160**: 216–9.
 - 37 Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. *Allergy* 2008; **63**:226–32.
 - 38 van Anrooij B, van der Veer E, de Monchy JG *et al.* Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. *J Allergy Clin Immunol* 2013; **132**:125–30.
 - 39 Alvarez-Twose I, Zanotti R, González-de-Olano D *et al.*; on behalf of the Spanish Network on Mastocytosis (REMA) and the Italian Network on Mastocytosis (RIMA). Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. *J Allergy Clin Immunol* 2014; **133**: 520–8.e5.
 - 40 Müller UR, Horat W, Wüthrich B, Conroy M, Reisman RE. Anaphylaxis after hymenoptera stings in three patients with urticaria pigmentosa. *J Allergy Clin Immunol* 1983; **72**:685–9.
 - 41 Kors JW, van Doormaal JJ, de Monchy JG. Anaphylactoid shock following hymenoptera sting as a presenting symptom of systemic mastocytosis. *J Intern Med* 1993; **233**:255–8.
 - 42 Oude Elberink JN, de Monchy JG, Kors JW, van Doormaal JJ, Dubois AE. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. *J Allergy Clin Immunol* 1997; **99**:153–4.
 - 43 Florian S, Krauth MT, Simonitsch-Klupp I *et al.* Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. *Int Arch Allergy Immunol* 2005; **136**:273–80.
 - 44 Bonadonna P, Perbellini O, Passalacqua G *et al.* Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. *J Allergy Clin Immunol* 2009; **123**:680–6.
 - 45 Bonadonna P, Zanotti R, Müller U. Mastocytosis and insect venom allergy. *Curr Opin Allergy Clin Immunol* 2010; **10**:347–53.
 - 46 Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. *Lancet* 1977; **1**:466–9.
 - 47 Mueller HL. Diagnosis and treatment of insect sensitivity. *J Asthma Res* 1966; **3**:331–3.
 - 48 Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. *J Allergy Clin Immunol* 2011; **128**(147–152):e2.
 - 49 Valent P. Mast cell activation syndromes: definition and classification. *Allergy* 2013; **68**:417–24.
 - 50 Frieri M, Patel R, Celestin J. Mast cell activation syndrome: a review. *Curr Allergy Asthma Rep* 2013; **13**:27–32.
 - 51 Picard M, Giavina-Bianchi P, Mezzano V, Castells M. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. *Clin Ther* 2013; **35**:548–62.
 - 52 Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Nöthen MM. Familial occurrence of systemic mast cell activation disease. *PLoS ONE* 2013; **8**: e76241.
 - 53 Awad JA, Morrow JD, Roberts LJ. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. *J Allergy Clin Immunol* 1994; **93**:817–24.
 - 54 Di Lorenzo G, Pacor ML, Vignola AM *et al.* Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients. *Allergy* 2002; **57**:1180–6.
 - 55 van Toorenenbergen AW, Oranje AP. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis. *Clin Chim Acta* 2005; **359**:72–7.
 - 56 Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. *Int Arch Allergy Immunol* 2008; **147**:338–43.
 - 57 Furitsu T, Tsujimura T, Tono T *et al.*, *et al.* Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. *J Clin Invest* 1993; **92**:1736–44.
 - 58 Bischoff SC, Dahinden CA. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. *J Exp Med* 1992; **175**:237–44.
 - 59 Columbo M, Horowitz EM, Botana LM *et al.* The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. *J Immunol* 1992; **149**:599–608.
 - 60 Sperr WR, Czerwenka K, Mundigler G *et al.* Specific activation of human mast cells by the ligand for c-kit: comparison between lung, uterus and heart mast cells. *Int Arch Allergy Immunol* 1993; **102**:170–5.
 - 61 Fricker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. *J Allergy Clin Immunol* 1997; **100**:11–5.
 - 62 González de Olano D, Alvarez-Twose I, Esteban-López MI *et al.* Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. *J Allergy Clin Immunol* 2008; **121**:519–26.
 - 63 Niedozytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. *Allergy* 2009; **64**:1237–45.
 - 64 Böhm A, Sonneck K, Gleixner KV *et al.* In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. *Exp Hematol* 2010; **38**:744–55.
 - 65 Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P. Severe life-threatening

- or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. *Int Arch Allergy Immunol* 2012; **157**(4):399–405.
- 66 Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. *Immunol Allergy Clin North Am* 2006; **26**:575–92.
 - 67 Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. *Cancer* 2006; **107**:1429–39.
 - 68 Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. *Leuk Res* 2011; **35**:1143–52.
 - 69 Gleixner KV, Mayerhofer M, Aichberger KJ *et al.* PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. *Blood* 2006; **107**:752–9.
 - 70 Gotlib J, Berubé C, Growney JD *et al.* Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. *Blood* 2005; **106**:2865–70.
 - 71 Gotlib J, Kluin-Nelemans HC, George TI *et al.* KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. *Blood* 2012; **120** (ASH abstract 799).
 - 72 Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. *Cancer* 2006; **107**:345–51.
 - 73 Verstovsek S, Tefferi A, Cortes J *et al.* Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. *Clin Cancer Res* 2008; **14**:3906–15.
 - 74 Paul C, Sans B, Suarez F *et al.* Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. *Am J Hematol* 2010; **85**:921–5.
 - 75 Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. *Clin Exp Allergy* 2009; **39**:1711–20.
 - 76 Siebenhaar F, Kühn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. *J Allergy Clin Immunol* 2007; **120**:213–5.
 - 77 Molderings GJ, Raithel M, Kratz F *et al.* Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. *Intern Med* 2011; **50**:611–5.